FMS — Fresenius Medical Care AG & Co. KGaA stock price, charts and financials

QT55Fresenius Medical Care AG & Co. KGaA

NYSE·Healthcare·Medical - Care Facilities·Germany

Latest market price

24.01

-1.25-4.95%

Overview Short InterestFilings

FMSQT55Fresenius Medical Care AG & Co. KGaA·NYSE

Overview Short InterestFilings

24.01-4.95%

News

Down 4.9% — U.S. treatment volumes fell further, pressuring near-term operational performance despite Q2 profit beat.

High confidence

Loading chart...

Signal & projected range

Gap down — mean-reversionHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

DVA-2.44%$227.99 EHC-1.75%$110.50 ENSG-0.62%$176.13 UHS-0.69%$167.87 THC+1.34%$253.33 CHE-0.16%$539.72 PACS+0.70%$44.81 CON-1.83%$31.12

Snapshot

Index	-	P/E	12.57	EPS (ttm)	1.91	Insider Own	-	Shs Outstand	537.13M	Perf Week	-2.99%

Market Cap	12.90B	Forward P/E	9.53	EPS next Y	2.52	Insider Trans	-	Shs Float	490.47M	Perf Month	1.69%

Enterprise Value	23.08B	PEG	0.93	EPS next Q	-	Inst Own	-	Short Float	0.55%	Perf Quarter	6.00%

Income	1.09B	P/S	0.57	EPS this Y	21.12%	Inst Trans	-	Short Ratio	3.58	Perf Half Y	6.24%

Sales	22.44B	P/B	0.79	EPS next Y	8.88%	ROA	3.00%	Short Interest	2.68M	Perf YTD	0.80%

Book/sh	30.57	P/C	6.87	EPS next 5Y	13.53%	ROE	7.16%	52W High	27.64 -13.13%	Perf Year	-4.46%

Cash/sh	3.49	P/FCF	6.69	EPS past 3/5Y	46.77% 4.87%	ROIC	5.76%	52W Low	20.02 19.93%	Perf 3Y	-8.64%

Dividend Est.	0.86 (3.60%)	EV/EBITDA	5.82	Sales past 3/5Y	2.77% 1.69%	Gross Margin	25.96%	Volatility	2.80% 1.62%	Perf 5Y	-40.55%

Dividend TTM	0.86 (3.60%)	EV/Sales	1.03	EPS Y/Y TTM	91.89%	Oper. Margin	10.17%	ATR (14)	0.63	Perf 10Y	-46.01%

Dividend Ex-Date	May 22, 2026	Quick Ratio	0.86	Sales Y/Y TTM	7.29%	Profit Margin	4.88%	RSI (14)	47.14	Recom	2.85

Dividend Gr. 3/5Y	4.74% 2.87%	Current Ratio	1.20	EPS Q/Q	20.45%	SMA20	-1.98%	Beta	0.73	Target Price	19.90

Payout	44.71%	Debt/Eq	0.71	Sales Q/Q	5.14%	SMA50	2.83%	Rel Volume	2.10	Prev Close	25.26

Employees	108,165	LT Debt/Eq	0.60	Earnings	Nov 03	SMA200	2.76%	Avg Volume	794.84K	Price	24.01

IPO Date	Sep 17, 1996	Option/Short	Yes / Yes	EPS/Sales Surpr.	-13.74% -1.82%	Net Debt/EBITDA	2.82	Volume	1,672,626	Change	-4.95%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-28-26	Reiterated	BNP Paribas		$20
Jan-20-26	Downgrade	Goldman Sachs	Buy → Neutral
Jan-05-26	Reiterated	Truist Financial	Hold	$26 → $28
Oct-15-25	Downgrade	B of A Securities	Neutral → Underperform
Sep-02-25	Downgrade	UBS	Neutral → Sell
May-15-24	Reiterated	Truist Securities	Hold	$27 → $24
Nov-24-23	Upgrade	HSBC	Reduce → Hold
Jan-02-23	Reiterated	Jefferies	Hold	$12
Jun-22-22	Reiterated	Truist Securities	Hold	$27
Nov-11-21	Upgrade	Jefferies	Underperform → Hold

Latest News

Aug-04-26

Aug-04-2612:39PM

Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcriptseekingalpha.com

06:04AM

Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlightsmarketbeat.com

05:35AM

Fresenius Medical Care Shares Drop After U.S. Treatment Volumes Fall Furtherwsj.com

03:44AM

Kioxia Showcases Flash Storage Innovations for the AI Era at FMS 2026businesswire.com

02:34AM

Dialysis firm FMC's shares slide despite earnings beat as US volumes disappoint againreuters.com

Aug-03-26

Aug-03-2601:46PM

Fresenius Medical Care beats quarterly profit estimates, sticks to 2026 outlookreuters.com

09:00AM

Silicon Motion Showcases Next-Generation Storage Solutions for Agentic AI Applications at FMS 2026businesswire.com

09:00AM

Marvell to Showcase Advanced AI Memory and Storage Infrastructure Portfolio for Agentic AI Inference at FMS 2026businesswire.com

Jul-29-26

Jul-29-2601:00PM

Fresenius Medical Care announces BEACON-US, generating real-world evidence supporting high-volume hemodiafiltration for U.S. dialysis patientsYahoo

Jul-24-26

Jul-24-2612:30AM

Quest Diagnostics Incorporated Q2 2026 Earnings Call SummaryYahoo

Jul-23-26

Jul-23-2609:35AM

Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citiproactiveinvestors.co.uk

07:00AM

Ryder Reports Second Quarter 2026 Resultsgurufocus.com

Jul-21-26

Jul-21-2609:32AM

Fresenius Medical Care: More Favorable Patient Outcomes Will Drive Growthseekingalpha.com

Jul-11-26

Jul-11-2605:28AM

Fresenius Medical: High Yield, Utilities-Like Stock At Valuation Lowsseekingalpha.com

Jul-08-26

Jul-08-2603:05PM

Reasons to Retain Fresenius Medical Stock in Your Portfolio for Nowzacks.com

Company

Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	22,443	22,143	20,919	21,042	20,400	20,836	20,367	19,575	19,528
Cost of Goods Sold Incl. D&A	16,616	16,469	15,773	15,715	15,253	15,192	14,052	13,531	13,444
Gross Profit	5,826	5,673	5,146	5,327	5,146	5,645	6,315	6,044	6,084
Selling, General and Administrative Excl. Other	3,513	3,421	3,400	3,457	3,334	3,279	3,574	3,396	3,381
Research and Development	177	178	199	251	240	261	221	188	158
Other Operating Expense	23	13	-40	138	-17	-86	-108	-82	0
Operating Income	2,113	2,061	1,588	1,481	1,590	2,191	2,628	2,542	3,585
Interest Expense	442	434	440	459	379	418	468	550	529
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	34	79	-4	95	71	87	48	69	173
Net Income Before Taxes	1,703	1,706	1,143	1,117	1,282	1,859	2,208	2,061	3,230
Income Taxes	351	362	342	325	342	417	571	450	603
Consolidated Net Income	1,095	1,104	582	540	708	1,146	1,328	1,344	2,339
Net Income From Continuing Operations	1,353	1,344	802	792	940	1,442	1,637	1,611	2,627
Net Income	1,095	1,104	582	540	708	1,146	1,328	1,344	2,339
EPS (Recurring)	1.91	1.90	1.00	0.92	0.60	0.98	1.49	1.51	3.82
EPS (Basic, Before Extraordinaries)	1.91	1.90	1.00	0.92	0.60	0.98	1.49	1.51	3.82
EPS (Diluted)	1.91	1.90	1.00	0.92	0.60	0.98	1.49	1.51	3.81
EBITDA	3,965	3,832	3,469	3,472	3,594	4,197	4,713	4,395	3,433
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	12.57	12.57	22.75	22.66	27.26	33.07	27.82	24.36	8.50
Price To Sales Ratio	0.59	0.63	0.64	0.58	0.94	1.83	1.81	1.67	1.02
Gross Margin	25.96	25.62	24.60	25.32	25.23	27.09	31.01	30.88	31.16
Operating Margin	9.41	9.31	7.59	7.04	7.79	10.52	12.90	12.99	18.36
Net Margin	4.88	4.99	2.78	2.57	3.47	5.50	6.52	6.87	11.98
Shares Outstanding	550	582	588	587	1,173	1,172	888	888	615
Market Capitalization	13,206	13,863	13,312	12,227	19,167	38,043	36,905	32,705	19,920
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.